PTMAP8

Across TCGA pan-cancer cohorts, PTMAP8 RNA is linked to patient survival in 20 of 34 cancer types, making it the most broadly survival-associated PTMAP8 data layer.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher PTMAP8 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated PTMAP8 expression acts as an unfavorable survival marker, although some lineages such as CESC and OV show a favorable association.

LIHC, ACC, and CESC are the cancer types where PTMAP8 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	All	0.459	0.625	<.001	61	view →
ACC	OS	Median	II,III,IV	0.396	0.723	.002	58	view →
CESC	OS	Tertile	All	0.871	0.704	.002	56	view →
OV	OS	Median	IV	0.495	0.262	.001	28	view →
UCS	DFS	Tertile	IV	0.938	0.237	.024	24	view →
LUAD	OS	Median	All	0.772	0.851	.002	23	view →
DLBC	DFS	Median	All	0.336	0.858	.005	22	view →
PAAD	OS	Tertile	All	0.353	0.595	.004	20	view →
SKCM	OS	Quartile	III,IV	0.807	0.493	.010	18	view →
STAD	DFS	Median	III,IV	0.461	0.751	.002	18	view →
LGG	OS	Quartile	All	0.847	0.929	.004	15	view →
UCEC	DFS	Median	III,IV	0.843	0.743	.022	12	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 20 lineages.

PTMAP8–LIHC (DFS)

Open the LIHC breakdown →